Newsroom

Drafts & Discoveries 2026: Cambridge, MA | Event Highlights

info@editco.bio (EditCo) — Tue, 23 Jun 2026 22:29:36 GMT

A look back at conversations shaping targeted protein degradation and advances in genome engineering and cell models.

Draughts & Discoveries 2026: Cambridge | UK Event Highlights

info@editco.bio (EditCo) — Tue, 31 Mar 2026 18:15:17 GMT

A look back at conversations shaping genome engineering and cell model innovation.

EditCo Bio & Promega Partner to Advance Cell-Based Research

info@editco.bio (EditCo) — Tue, 22 Apr 2025 13:13:14 GMT

EditCo’s robust, HiBiT-tagged CRISPR knock-ins transform cells into powerful biosensors — perfect for drug discovery, cell-based assays, and protein quantification.
Through this partnership, EditCo Bio expands its capabilities by incorporating Promega’s proprietary bioluminescent and protein-labeling technologies into its CRISPR-engineered cell lines, ensuring precise gene edits with functional validation.

CRISPR Genome Editing Advances Disease Modeling

Biocompare — Thu, 20 Mar 2025 18:41:25 GMT

This Editorial article was published on Biocompare.

EditCo Launches XDel Knockout Cells for Reliable CRISPR

info@editco.bio (EditCo) — Tue, 28 Jan 2025 19:17:57 GMT

REDWOOD CITY, Calif.--EditCo Bio, a leader in cutting-edge genetic engineering and cellular model solutions, today announced the launch of XDel Knockout Cells, an innovative product designed to revolutionize the field of CRISPR gene editing. By leveraging a groundbreaking guide RNA (gRNA) design strategy, XDel technology ensures robust, reliable, and reproducible gene knockout results that accelerate research in functional genomics, disease modeling, and drug development.

Viewpoints: The Evolution of CRISPR Technology

Travis Hardcastle — Tue, 27 Aug 2024 21:21:27 GMT

This article is also published on Biocompare.

EditCo Unveils Knockout CD4+ T-Cell Pools for Research

info@editco.bio (EditCo) — Thu, 18 Apr 2024 14:15:00 GMT

REDWOOD CITY, CA, April 18, 2024 – EditCo Bio, Inc., a pioneer at the forefront of genome engineering innovation, today announced the launch of its Knockout CD4+ T-cell Pools. This latest addition to EditCo Bio’s product lineup marks a significant leap forward in CRISPR-mediated gene editing, providing the scientific community with an advanced tool for primary T-cell editing that surpasses the capabilities of traditional methodologies.